Vir Biotechnology, Inc. (NASDAQ: VIR) Stock Competitors & Peer Comparison
See VIR's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for VIR and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| VIR | $10.88 | +2.64% | 1.8B | -5.85 | -$1.86 | N/A |
| VRTX | $510.72 | +0.47% | 129.6B | 26.83 | $19.03 | N/A |
| REGN | $798.17 | +1.70% | 82.2B | 17.49 | $45.63 | +0.47% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| MRNA | $172.94 | +12.27% | 68.6B | -21.22 | -$8.15 | N/A |
| ARGX | $988.20 | -0.21% | 61.5B | 35.63 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $192.76 | +0.95% | 41B | -21.85 | -$8.82 | N/A |
| RVMDW | $9.98 | +3.47% | 39.3B | -1.13 | -$8.82 | N/A |
| ONC | $365.67 | +4.23% | 39.1B | 64.38 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
VIR vs VRTX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, VRTX has a market cap of 129.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while VRTX trades at $510.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas VRTX's P/E ratio is 26.83. In terms of profitability, VIR's ROE is -0.30%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, VIR is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
VIR vs REGN Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, REGN has a market cap of 82.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while REGN trades at $798.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas REGN's P/E ratio is 17.49. In terms of profitability, VIR's ROE is -0.30%, compared to REGN's ROE of +0.14%. Regarding short-term risk, VIR is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for VIR.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
VIR vs VRNA Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas VRNA's P/E ratio is -102.80. In terms of profitability, VIR's ROE is -0.30%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, VIR is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for VIR.Check VRNA's competition here
Moderna, Inc. (NASDAQ: MRNA)
VIR vs MRNA Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, MRNA has a market cap of 68.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while MRNA trades at $172.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas MRNA's P/E ratio is -21.22. In terms of profitability, VIR's ROE is -0.30%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, VIR is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for VIR.Check MRNA's competition here
argenx SE (NASDAQ: ARGX)
VIR vs ARGX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ARGX has a market cap of 61.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ARGX trades at $988.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ARGX's P/E ratio is 35.63. In terms of profitability, VIR's ROE is -0.30%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, VIR is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
VIR vs SGEN Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas SGEN's P/E ratio is -57.19. In terms of profitability, VIR's ROE is -0.30%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, VIR is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for VIR.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
VIR vs RVMD Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, RVMD has a market cap of 41B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while RVMD trades at $192.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas RVMD's P/E ratio is -21.85. In terms of profitability, VIR's ROE is -0.30%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, VIR is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for VIR.Check RVMD's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
VIR vs RVMDW Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, RVMDW has a market cap of 39.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while RVMDW trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas RVMDW's P/E ratio is -1.13. In terms of profitability, VIR's ROE is -0.30%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, VIR is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for VIR.Check RVMDW's competition here
BeOne Medicines AG (NASDAQ: ONC)
VIR vs ONC Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ONC has a market cap of 39.1B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ONC trades at $365.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ONC's P/E ratio is 64.38. In terms of profitability, VIR's ROE is -0.30%, compared to ONC's ROE of +0.14%. Regarding short-term risk, VIR is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for VIR.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
VIR vs ALNY Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ALNY has a market cap of 32.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ALNY trades at $244.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ALNY's P/E ratio is 44.02. In terms of profitability, VIR's ROE is -0.30%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, VIR is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for VIR.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
VIR vs ROIV Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ROIV has a market cap of 28.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ROIV trades at $38.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ROIV's P/E ratio is -37.09. In terms of profitability, VIR's ROE is -0.30%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, VIR is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for VIR.Check ROIV's competition here
Insmed Incorporated (NASDAQ: INSM)
VIR vs INSM Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, INSM has a market cap of 26.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while INSM trades at $121.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas INSM's P/E ratio is -29.44. In terms of profitability, VIR's ROE is -0.30%, compared to INSM's ROE of -1.11%. Regarding short-term risk, VIR is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for VIR.Check INSM's competition here
Incyte Corporation (NASDAQ: INCY)
VIR vs INCY Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, INCY has a market cap of 25.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while INCY trades at $124.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas INCY's P/E ratio is 16.75. In terms of profitability, VIR's ROE is -0.30%, compared to INCY's ROE of +0.30%. Regarding short-term risk, VIR is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for VIR.Check INCY's competition here
BioNTech SE (NASDAQ: BNTX)
VIR vs BNTX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, BNTX has a market cap of 24.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while BNTX trades at $98.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas BNTX's P/E ratio is -12.71. In terms of profitability, VIR's ROE is -0.30%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, VIR is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check BNTX's competition here
Genmab A/S (NASDAQ: GMAB)
VIR vs GMAB Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, GMAB has a market cap of 21.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while GMAB trades at $34.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas GMAB's P/E ratio is 26.14. In terms of profitability, VIR's ROE is -0.30%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, VIR is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for VIR.Check GMAB's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
VIR vs UTHR Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, UTHR has a market cap of 20.9B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while UTHR trades at $493.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas UTHR's P/E ratio is 17.64. In terms of profitability, VIR's ROE is -0.30%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, VIR is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for VIR.Check UTHR's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
VIR vs BGNE Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas BGNE's P/E ratio is -22.55. In terms of profitability, VIR's ROE is -0.30%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, VIR is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for VIR.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
VIR vs DNA-WT Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, VIR's ROE is -0.30%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, VIR is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for VIR.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
VIR vs JAZZ Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, JAZZ has a market cap of 15.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while JAZZ trades at $241.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas JAZZ's P/E ratio is 9.00. In terms of profitability, VIR's ROE is -0.30%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, VIR is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for VIR.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
VIR vs ASND Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ASND has a market cap of 14.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ASND trades at $237.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ASND's P/E ratio is -98.18. In terms of profitability, VIR's ROE is -0.30%, compared to ASND's ROE of +1.90%. Regarding short-term risk, VIR is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for VIR.Check ASND's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
VIR vs NBIX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, NBIX has a market cap of 14.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while NBIX trades at $143.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas NBIX's P/E ratio is 20.80. In terms of profitability, VIR's ROE is -0.30%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, VIR is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check NBIX's competition here
Exelixis, Inc. (NASDAQ: EXEL)
VIR vs EXEL Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, EXEL has a market cap of 14.4B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while EXEL trades at $57.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas EXEL's P/E ratio is 16.35. In terms of profitability, VIR's ROE is -0.30%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, VIR is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for VIR.Check EXEL's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
VIR vs SMMT Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, SMMT has a market cap of 13.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while SMMT trades at $16.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas SMMT's P/E ratio is -15.09. In terms of profitability, VIR's ROE is -0.30%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, VIR is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for VIR.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
VIR vs HALO Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, HALO has a market cap of 13.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while HALO trades at $111.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas HALO's P/E ratio is 20.79. In terms of profitability, VIR's ROE is -0.30%, compared to HALO's ROE of +1.81%. Regarding short-term risk, VIR is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for VIR.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
VIR vs BBIO Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, BBIO has a market cap of 13B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while BBIO trades at $66.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas BBIO's P/E ratio is -17.80. In terms of profitability, VIR's ROE is -0.30%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, VIR is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for VIR.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
VIR vs KRTX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas KRTX's P/E ratio is -28.09. In terms of profitability, VIR's ROE is -0.30%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, VIR is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check KRTX's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
VIR vs BMRN Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, BMRN has a market cap of 12.4B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while BMRN trades at $64.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas BMRN's P/E ratio is 30.80. In terms of profitability, VIR's ROE is -0.30%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, VIR is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for VIR.Check BMRN's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
VIR vs MDGL Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, MDGL has a market cap of 12.1B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while MDGL trades at $521.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas MDGL's P/E ratio is -40.78. In terms of profitability, VIR's ROE is -0.30%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, VIR is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for VIR.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
VIR vs TECH Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while TECH trades at $72.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas TECH's P/E ratio is 37.36. In terms of profitability, VIR's ROE is -0.30%, compared to TECH's ROE of +0.09%. Regarding short-term risk, VIR is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for VIR.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
VIR vs RNAM Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas RNAM's P/E ratio is -17.39. In terms of profitability, VIR's ROE is -0.30%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, VIR is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for VIR.Check RNAM's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
VIR vs AXSM Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, AXSM has a market cap of 10.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while AXSM trades at $205.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas AXSM's P/E ratio is -53.65. In terms of profitability, VIR's ROE is -0.30%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, VIR is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for VIR.Check AXSM's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
VIR vs TWST Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, TWST has a market cap of 10.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while TWST trades at $165.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas TWST's P/E ratio is -74.69. In terms of profitability, VIR's ROE is -0.30%, compared to TWST's ROE of -0.30%. Regarding short-term risk, VIR is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for VIR.Check TWST's competition here
10x Genomics, Inc. (NASDAQ: TXG)
VIR vs TXG Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, TXG has a market cap of 10B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while TXG trades at $79.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas TXG's P/E ratio is -134.07. In terms of profitability, VIR's ROE is -0.30%, compared to TXG's ROE of -0.09%. Regarding short-term risk, VIR is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for VIR.Check TXG's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
VIR vs KRYS Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, KRYS has a market cap of 9.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while KRYS trades at $333.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas KRYS's P/E ratio is 41.84. In terms of profitability, VIR's ROE is -0.30%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, VIR is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for VIR.Check KRYS's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
VIR vs ARWR Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ARWR has a market cap of 9.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ARWR trades at $68.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ARWR's P/E ratio is -30.57. In terms of profitability, VIR's ROE is -0.30%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, VIR is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for VIR.Check ARWR's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
VIR vs KYMR Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, KYMR has a market cap of 9.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while KYMR trades at $117.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas KYMR's P/E ratio is -36.77. In terms of profitability, VIR's ROE is -0.30%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, VIR is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for VIR.Check KYMR's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
VIR vs RXDX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas RXDX's P/E ratio is -56.47. In terms of profitability, VIR's ROE is -0.30%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, VIR is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check RXDX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
VIR vs PTGX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, PTGX has a market cap of 9.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while PTGX trades at $144.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas PTGX's P/E ratio is 140.76. In terms of profitability, VIR's ROE is -0.30%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, VIR is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check PTGX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
VIR vs NUVL Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas NUVL's P/E ratio is -21.79. In terms of profitability, VIR's ROE is -0.30%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, VIR is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for VIR.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
VIR vs CRNX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CRNX's P/E ratio is -16.86. In terms of profitability, VIR's ROE is -0.30%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, VIR is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check CRNX's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
VIR vs IBRX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, IBRX has a market cap of 8.9B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while IBRX trades at $8.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas IBRX's P/E ratio is -8.71. In terms of profitability, VIR's ROE is -0.30%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, VIR is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check IBRX's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
VIR vs TGTX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, TGTX has a market cap of 8.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while TGTX trades at $57.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas TGTX's P/E ratio is 20.71. In terms of profitability, VIR's ROE is -0.30%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, VIR is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check TGTX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
VIR vs IMGN Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas IMGN's P/E ratio is -111.55. In terms of profitability, VIR's ROE is -0.30%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, VIR is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for VIR.Check IMGN's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
VIR vs CAI Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CAI has a market cap of 8.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CAI trades at $30.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CAI's P/E ratio is 86.12. In terms of profitability, VIR's ROE is -0.30%, compared to CAI's ROE of +0.19%. Regarding short-term risk, VIR is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for VIR.Check CAI's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
VIR vs PCVX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, PCVX has a market cap of 8.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while PCVX trades at $58.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas PCVX's P/E ratio is -7.72. In terms of profitability, VIR's ROE is -0.30%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, VIR is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check PCVX's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
VIR vs CYTK Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CYTK has a market cap of 8.4B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CYTK trades at $67.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CYTK's P/E ratio is -9.36. In terms of profitability, VIR's ROE is -0.30%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, VIR is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for VIR.Check CYTK's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
VIR vs BPMC Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas BPMC's P/E ratio is -51.58. In terms of profitability, VIR's ROE is -0.30%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, VIR is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for VIR.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
VIR vs APGE Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas APGE's P/E ratio is -31.19. In terms of profitability, VIR's ROE is -0.30%, compared to APGE's ROE of -0.30%. Regarding short-term risk, VIR is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for VIR.Check APGE's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
VIR vs PRAX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, PRAX has a market cap of 8.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while PRAX trades at $298.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas PRAX's P/E ratio is -23.11. In terms of profitability, VIR's ROE is -0.30%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, VIR is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check PRAX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
VIR vs CERE Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CERE's P/E ratio is -16.47. In terms of profitability, VIR's ROE is -0.30%, compared to CERE's ROE of -0.72%. Regarding short-term risk, VIR is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for VIR.Check CERE's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
VIR vs SYRE Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, SYRE has a market cap of 8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while SYRE trades at $92.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas SYRE's P/E ratio is -47.19. In terms of profitability, VIR's ROE is -0.30%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, VIR is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for VIR.Check SYRE's competition here
Immunovant, Inc. (NASDAQ: IMVT)
VIR vs IMVT Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, IMVT has a market cap of 7.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while IMVT trades at $37.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas IMVT's P/E ratio is -13.18. In terms of profitability, VIR's ROE is -0.30%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, VIR is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for VIR.Check IMVT's competition here
Abivax S.A. (NASDAQ: ABVX)
VIR vs ABVX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ABVX has a market cap of 7.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ABVX trades at $103.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ABVX's P/E ratio is -19.69. In terms of profitability, VIR's ROE is -0.30%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, VIR is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check ABVX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
VIR vs IONS Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, IONS has a market cap of 7.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while IONS trades at $44.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas IONS's P/E ratio is -13.73. In terms of profitability, VIR's ROE is -0.30%, compared to IONS's ROE of -1.11%. Regarding short-term risk, VIR is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for VIR.Check IONS's competition here
Metsera, Inc. (NASDAQ: MTSR)
VIR vs MTSR Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas MTSR's P/E ratio is -23.58. In terms of profitability, VIR's ROE is -0.30%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, VIR is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for VIR.Check MTSR's competition here
Belite Bio, Inc (NASDAQ: BLTE)
VIR vs BLTE Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, BLTE has a market cap of 7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while BLTE trades at $173.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas BLTE's P/E ratio is -92.73. In terms of profitability, VIR's ROE is -0.30%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, VIR is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for VIR.Check BLTE's competition here
CG Oncology Inc. (NASDAQ: CGON)
VIR vs CGON Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CGON has a market cap of 6.9B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CGON trades at $78.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CGON's P/E ratio is -29.09. In terms of profitability, VIR's ROE is -0.30%, compared to CGON's ROE of -0.25%. Regarding short-term risk, VIR is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for VIR.Check CGON's competition here
Merus N.V. (NASDAQ: MRUS)
VIR vs MRUS Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas MRUS's P/E ratio is -17.05. In terms of profitability, VIR's ROE is -0.30%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, VIR is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for VIR.Check MRUS's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
VIR vs RYTM Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, RYTM has a market cap of 6.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while RYTM trades at $98.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas RYTM's P/E ratio is -31.78. In terms of profitability, VIR's ROE is -0.30%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, VIR is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for VIR.Check RYTM's competition here
Arcellx, Inc. (NASDAQ: ACLX)
VIR vs ACLX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ACLX's P/E ratio is -28.27. In terms of profitability, VIR's ROE is -0.30%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, VIR is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
VIR vs RETA Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas RETA's P/E ratio is -66.29. In terms of profitability, VIR's ROE is -0.30%, compared to RETA's ROE of +0.47%. Regarding short-term risk, VIR is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for VIR.Check RETA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
VIR vs CNTA Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CNTA's P/E ratio is -22.63. In terms of profitability, VIR's ROE is -0.30%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, VIR is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for VIR.Check CNTA's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
VIR vs TVTX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, TVTX has a market cap of 5.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while TVTX trades at $62.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas TVTX's P/E ratio is -139.69. In terms of profitability, VIR's ROE is -0.30%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, VIR is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check TVTX's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
VIR vs LGND Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, LGND has a market cap of 5.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while LGND trades at $290.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas LGND's P/E ratio is 31.84. In terms of profitability, VIR's ROE is -0.30%, compared to LGND's ROE of +0.20%. Regarding short-term risk, VIR is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for VIR.Check LGND's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
VIR vs SRRK Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, SRRK has a market cap of 5.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while SRRK trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas SRRK's P/E ratio is -13.96. In terms of profitability, VIR's ROE is -0.30%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, VIR is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for VIR.Check SRRK's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
VIR vs ORKA Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ORKA has a market cap of 5.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ORKA trades at $93.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ORKA's P/E ratio is -48.13. In terms of profitability, VIR's ROE is -0.30%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, VIR is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for VIR.Check ORKA's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
VIR vs CRSP Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CRSP has a market cap of 5.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CRSP trades at $58.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CRSP's P/E ratio is -12.25. In terms of profitability, VIR's ROE is -0.30%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, VIR is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for VIR.Check CRSP's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
VIR vs CDTX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CDTX's P/E ratio is -19.77. In terms of profitability, VIR's ROE is -0.30%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, VIR is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check CDTX's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
VIR vs MIRM Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, MIRM has a market cap of 5.6B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while MIRM trades at $92.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas MIRM's P/E ratio is -6.32. In terms of profitability, VIR's ROE is -0.30%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, VIR is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for VIR.Check MIRM's competition here
Abcam plc (NASDAQ: ABCM)
VIR vs ABCM Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, VIR's ROE is -0.30%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, VIR is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for VIR.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
VIR vs ISEE Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ISEE's P/E ratio is -22.44. In terms of profitability, VIR's ROE is -0.30%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, VIR is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for VIR.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
VIR vs COGT Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, COGT has a market cap of 5.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while COGT trades at $32.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas COGT's P/E ratio is -15.17. In terms of profitability, VIR's ROE is -0.30%, compared to COGT's ROE of -0.73%. Regarding short-term risk, VIR is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for VIR.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
VIR vs PTCT Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while PTCT trades at $65.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas PTCT's P/E ratio is -28.01. In terms of profitability, VIR's ROE is -0.30%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, VIR is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for VIR.Check PTCT's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
VIR vs DNTH Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, DNTH has a market cap of 5.4B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while DNTH trades at $96.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas DNTH's P/E ratio is -23.25. In terms of profitability, VIR's ROE is -0.30%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, VIR is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for VIR.Check DNTH's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
VIR vs APLS Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas APLS's P/E ratio is 38.35. In terms of profitability, VIR's ROE is -0.30%, compared to APLS's ROE of +0.40%. Regarding short-term risk, VIR is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for VIR.Check APLS's competition here
Erasca, Inc. (NASDAQ: ERAS)
VIR vs ERAS Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ERAS has a market cap of 5.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ERAS trades at $15.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ERAS's P/E ratio is -16.17. In terms of profitability, VIR's ROE is -0.30%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, VIR is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for VIR.Check ERAS's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
VIR vs DFTX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, DFTX has a market cap of 5.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while DFTX trades at $39.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas DFTX's P/E ratio is N/A. In terms of profitability, VIR's ROE is -0.30%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, VIR is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check DFTX's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
VIR vs EWTX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, EWTX has a market cap of 4.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while EWTX trades at $44.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas EWTX's P/E ratio is -24.13. In terms of profitability, VIR's ROE is -0.30%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, VIR is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check EWTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
VIR vs TERN Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas TERN's P/E ratio is -51.41. In terms of profitability, VIR's ROE is -0.30%, compared to TERN's ROE of -0.20%. Regarding short-term risk, VIR is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for VIR.Check TERN's competition here
Veradermics, Incorporated (NYSE: MANE)
VIR vs MANE Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, MANE has a market cap of 4.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while MANE trades at $112.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas MANE's P/E ratio is -35.94. In terms of profitability, VIR's ROE is -0.30%, compared to MANE's ROE of -0.38%. Regarding short-term risk, VIR is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for VIR.Check MANE's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
VIR vs FOLD Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas FOLD's P/E ratio is -161.00. In terms of profitability, VIR's ROE is -0.30%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, VIR is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for VIR.Check FOLD's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
VIR vs IOVA Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, IOVA has a market cap of 4.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while IOVA trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas IOVA's P/E ratio is -13.96. In terms of profitability, VIR's ROE is -0.30%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, VIR is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for VIR.Check IOVA's competition here
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD)
VIR vs ACAD Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ACAD trades at $26.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ACAD's P/E ratio is 11.89. In terms of profitability, VIR's ROE is -0.30%, compared to ACAD's ROE of +0.32%. Regarding short-term risk, VIR is less volatile compared to ACAD. This indicates lower risk in terms of short-term price fluctuations for VIR.Check ACAD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
VIR vs AKRO Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas AKRO's P/E ratio is -14.57. In terms of profitability, VIR's ROE is -0.30%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, VIR is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for VIR.Check AKRO's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
VIR vs ADPT Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ADPT has a market cap of 4.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ADPT trades at $27.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ADPT's P/E ratio is -67.95. In terms of profitability, VIR's ROE is -0.30%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, VIR is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for VIR.Check ADPT's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
VIR vs ALPN Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ALPN's P/E ratio is -101.52. In terms of profitability, VIR's ROE is -0.30%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, VIR is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for VIR.Check ALPN's competition here
Parabilis Medicines, Inc. (NASDAQ: PBLS)
VIR vs PBLS Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, PBLS has a market cap of 4.3B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while PBLS trades at $36.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas PBLS's P/E ratio is -19.64. In terms of profitability, VIR's ROE is -0.30%, compared to PBLS's ROE of -0.15%. Regarding short-term risk, VIR is less volatile compared to PBLS. This indicates lower risk in terms of short-term price fluctuations for VIR.Check PBLS's competition here
Opthea Limited (NASDAQ: OPT)
VIR vs OPT Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas OPT's P/E ratio is -1.52. In terms of profitability, VIR's ROE is -0.30%, compared to OPT's ROE of +1.18%. Regarding short-term risk, VIR is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for VIR.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
VIR vs PRTC Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas PRTC's P/E ratio is -3.78. In terms of profitability, VIR's ROE is -0.30%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, VIR is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for VIR.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
VIR vs MRTX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas MRTX's P/E ratio is -4.82. In terms of profitability, VIR's ROE is -0.30%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, VIR is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check MRTX's competition here
Celcuity Inc. (NASDAQ: CELC)
VIR vs CELC Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CELC has a market cap of 4.1B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CELC trades at $84.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CELC's P/E ratio is -19.53. In terms of profitability, VIR's ROE is -0.30%, compared to CELC's ROE of -3.51%. Regarding short-term risk, VIR is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for VIR.Check CELC's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
VIR vs RLAY Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, RLAY has a market cap of 4B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while RLAY trades at $18.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas RLAY's P/E ratio is -11.59. In terms of profitability, VIR's ROE is -0.30%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, VIR is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for VIR.Check RLAY's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
VIR vs ABCL Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, ABCL has a market cap of 3.9B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while ABCL trades at $12.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas ABCL's P/E ratio is -23.44. In terms of profitability, VIR's ROE is -0.30%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, VIR is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for VIR.Check ABCL's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
VIR vs CPRX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CPRX's P/E ratio is 12.30. In terms of profitability, VIR's ROE is -0.30%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, VIR is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for VIR.Check CPRX's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
VIR vs TLX Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, TLX has a market cap of 3.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while TLX trades at $11.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas TLX's P/E ratio is 118.06. In terms of profitability, VIR's ROE is -0.30%, compared to TLX's ROE of +0.07%. Regarding short-term risk, VIR is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for VIR.Check TLX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
VIR vs XENE Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while XENE trades at $38.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas XENE's P/E ratio is -8.30. In terms of profitability, VIR's ROE is -0.30%, compared to XENE's ROE of -0.44%. Regarding short-term risk, VIR is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for VIR.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
VIR vs RYZB Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas RYZB's P/E ratio is -57.86. In terms of profitability, VIR's ROE is -0.30%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, VIR is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for VIR.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
VIR vs CBAY Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas CBAY's P/E ratio is -32.81. In terms of profitability, VIR's ROE is -0.30%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, VIR is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for VIR.Check CBAY's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
VIR vs IDYA Comparison September 2026
Vir Biotechnology, Inc. (NASDAQ: VIR) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, VIR stands at 1.8B. In comparison, IDYA has a market cap of 3.7B. Regarding current trading prices, VIR is priced at $10.88 on the NASDAQ, while IDYA trades at $38.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
VIR currently has a P/E ratio of -5.85, whereas IDYA's P/E ratio is -20.03. In terms of profitability, VIR's ROE is -0.30%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, VIR is more volatile compared to IDYA. This indicates higher risk in terms of short-term price fluctuations for VIR.Check IDYA's competition here